Warning: The NCBI web site requires JavaScript to function. more...
PGRMC1: a new biomarker for the estrogen receptor in breast cancer.
Craven RJ.
Breast Cancer Res. 2008;10(6):113. Epub 2008 Nov 24.
Related citations
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, Vogel U, Sotlar K, Wallwiener D, Kurek R, Fehm T, Cahill MA.
Breast Cancer Res. 2008;10(5):R85. Epub 2008 Oct 15. Erratum in: Breast Cancer Res. 2009;11(1):401.
Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells.
Neubauer H, Adam G, Seeger H, Mueck AO, Solomayer E, Wallwiener D, Cahill MA, Fehm T.
Climacteric. 2009 Jun;12(3):230-9.
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
Acta Oncol. 2009;48(4):522-31.
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa, Bhurgri Y, Raza F, Kayani N.
Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6.
Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
Nahleh Z.
Future Oncol. 2008 Feb;4(1):15-21. Review.
Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer.
Albert JM, Gonzalez-Angulo AM, Guray M, Sahin A, Tereffe W, Woodward WA, Strom EA, Hunt KK, Tucker SL, Buchholz TA.
Cancer. 2011 Apr 15;117(8):1595-601. doi: 10.1002/cncr.25694. Epub 2010 Nov 8.
Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging.
Causey MW, Huston LJ, Harold DM, Charaba CJ, Ippolito DL, Hoffer ZS, Brown TA, Stallings JD.
J Surg Res. 2011 Dec;171(2):615-22. Epub 2010 May 20.
Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease?
Zhu K, Bernard LJ, Levine RS, Williams SM.
Med Hypotheses. 1997 Jul;49(1):69-75. Review.
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T.
APMIS. 2009 Sep;117(9):644-50.
WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH, Hecht JL, Pinkus JL, Pinkus GS.
Am J Clin Pathol. 2002 May;117(5):745-50.
Nuclear binding of the estrogen receptor: a potential predictor for hormone response in metastatic breast cancer.
Robert NJ, Martin L, Taylor CD, Popkin J, Parkinson DR, White C, Pappas CA, Tamura H, Gelman R, Cohen J, et al.
Breast Cancer Res Treat. 1990 Oct;16(3):273-8.
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.
PLoS One. 2009;4(3):e4710. Epub 2009 Mar 9.
Proficiency testing of immunohistochemical biomarker assays in breast cancer.
Wasielewski R, Hasselmann S, Rüschoff J, Fisseler-Eckhoff A, Kreipe H.
Virchows Arch. 2008 Dec;453(6):537-43. Epub 2008 Oct 29.
Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
Kok M, Koornstra RH, Margarido TC, Fles R, Armstrong NJ, Linn SC, Van't Veer LJ, Weigelt B.
J Pathol. 2009 Jul;218(3):316-26.
Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ.
Anticancer Res. 2009 May;29(5):1557-62.
Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers.
Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y.
Int J Clin Oncol. 2008 Oct;13(5):431-5. Epub 2008 Oct 23.
Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications.
Badve S, Nakshatri H.
J Clin Pathol. 2009 Jan;62(1):6-12. Epub 2008 Sep 15. Review.
Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
Stark A, Schultz D, Kapke A, Nadkarni P, Burke M, Linden M, Raju U.
Eur J Surg Oncol. 2009 Sep;35(9):928-35. Epub 2009 Jan 1.
Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.
Suzuki R, Orsini N, Saji S, Key TJ, Wolk A.
Int J Cancer. 2009 Feb 1;124(3):698-712.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on